Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Sofosbuvir/velpatasvir fo… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden

Artikel i vetenskaplig tidskrift
Författare V. Isakov
V. Chulanov
D. Abdurakhmanov
E. Burnevich
E. Nurmukhametova
G. Kozhevnikova
N. Gankina
S. Zhuravel
S. Romanova
R. H. Hyland
S. Lu
E. S. Svarovskaia
J. McNally
D. M. Brainard
V. Ivashkin
V. Morozov
I. Bakulin
Martin Lagging
K. Zhdanov
O. Weiland
Publicerad i Infectious Diseases
Volym 51
Nummer/häfte 2
Sidor 131-139
ISSN 2374-4235
Publiceringsår 2019
Publicerad vid Institutionen för biomedicin, avdelningen för infektionssjukdomar
Sidor 131-139
Språk en
Länkar dx.doi.org/10.1080/23744235.2018.15...
Ämnesord Direct-acting antivirals, hepatitis C virus, pangenotypic, sofosbuvir, sustained virologic response, patient-reported outcomes, chronic hepatitis-c, future disease burden, virus-infection, genotype 1, sofosbuvir, velpatasvir, ribavirin, efficacy, boceprevir, Infectious Diseases
Ämneskategorier Invärtesmedicin

Sammanfattning

Background: In both Russia and Sweden, the dominant hepatitis C virus (HCV) is genotype 1, but around one-third of patients have genotype 3 infection. For such countries, HCV genotype testing is recommended prior to therapy. An effective pangenotypic therapy may potentially eliminate the need for genotyping. In this study, we evaluated the efficacy and safety of sofosbuvir/velpatasvir for 12 weeks in patients from Russia and Sweden. Methods: In an open-label, single-arm phase-3 study, patients could have HCV genotype 1-6 infection and were treatment-naive or interferon treatment-experienced. All patients received sofosbuvir/velpatasvir, once daily for 12 weeks. The primary endpoint was sustained virologic response 12 weeks post-treatment (SVR12). Results: Of 122 patients screened, 119 were enrolled and treated. Overall, half (50%) were male, 18% had cirrhosis, and 24% had failed prior interferon-based therapy. In total, 66% of patients were infected with HCV genotype 1 (59% 1b and 7% 1a), 6% with genotype 2, and 29% with genotype 3. The overall SVR12 rate was 99% (118/119, 95% confidence interval 95-100%). One treatment-experienced patient infected with HCV genotype 3 experienced virologic relapse after completing treatment. The most common adverse events were headache (16%) and fatigue (7%). Serious adverse events were observed in four patients, but none were related to treatment. No patients discontinued treatment due to adverse events. Conclusion: Sofosbuvir/velpatasvir as a pangenotypic treatment for 12 weeks was highly effective in patients from Russia and Sweden infected with HCV genotypes 1, 2, or 3. Sofosbuvir/velpatasvir was safe and well-tolerated.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?